8-hydroxy-2-(di-n-propylamino)tetralin has been researched along with Disease Models, Animal in 167 studies
8-Hydroxy-2-(di-n-propylamino)tetralin: A serotonin 1A-receptor agonist that is used experimentally to test the effects of serotonin.
8-OH-DPAT : A tetralin substituted at positions 1 and 7 by hydroxy and dipropylamino groups respectively
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Outcome of imipramine (IMI) treatment was scrutinized on progression of haloperidol instigated tardive dyskinesia (TD)." | 7.83 | Co-treatment with imipramine averted haloperidol-instigated tardive dyskinesia: Association with serotonin in brain regions. ( Haleem, DJ; Samad, N; Yasmin, F, 2016) |
| "The present study was undertaken to evaluate the potential role of 5-HT(1A) receptors and opioids receptors in the analgesic effect of tramadol in neuropathic pain." | 7.74 | Role of serotonin 5-HT1A and opioid receptors in the antiallodynic effect of tramadol in the chronic constriction injury model of neuropathic pain in rats. ( Berrocoso, E; De Benito, MD; Mico, JA, 2007) |
| " In the present study, we examined the effect of perospirone on marble-burying behavior, which has been considered an animal model of obsessive-compulsive disorder (OCD), compared with the effects of other antipsychotics such as haloperidol and risperidone." | 7.73 | Perospirone, a novel antipsychotic drug, inhibits marble-burying behavior via 5-HT1A receptor in mice: implications for obsessive-compulsive disorder. ( Egashira, N; Fujiwara, M; Harada, S; Iwasaki, K; Matsushita, M; Mishima, K; Nishimura, R; Okuno, R, 2005) |
| "The anxiolytic effects of aniracetam have not been proven in animals despite its clinical usefulness for post-stroke anxiety." | 7.71 | Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism. ( Kurasawa, M; Nakamura, K, 2001) |
| "Catalepsy was measured in rats using both the cross-legged position test and the bar test." | 5.31 | Repeated treatment with 8-OH-DPAT induces tolerance to its ability to produce the 5-HT1A behavioural syndrome, but not to its ability to attenuate haloperidol-induced catalepsy. ( Colpaert, FC; Kleven, MS; Koek, W; Prinssen, EP, 2000) |
| "Outcome of imipramine (IMI) treatment was scrutinized on progression of haloperidol instigated tardive dyskinesia (TD)." | 3.83 | Co-treatment with imipramine averted haloperidol-instigated tardive dyskinesia: Association with serotonin in brain regions. ( Haleem, DJ; Samad, N; Yasmin, F, 2016) |
| "The present study was undertaken to evaluate the potential role of 5-HT(1A) receptors and opioids receptors in the analgesic effect of tramadol in neuropathic pain." | 3.74 | Role of serotonin 5-HT1A and opioid receptors in the antiallodynic effect of tramadol in the chronic constriction injury model of neuropathic pain in rats. ( Berrocoso, E; De Benito, MD; Mico, JA, 2007) |
| "This study analyzes the long-term effects of ovariectomy on the basal experimental anxiety of rats and the influence of this condition on the anxiolytic properties of diazepam and the 5-HT(1A) receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT)." | 3.73 | Influence of the post-ovariectomy time frame on the experimental anxiety and the behavioural actions of some anxiolytic agents. ( Estrada-Camarena, E; Hernandez-Aragon, A; Picazo, O, 2006) |
| " In the present study, we examined the effect of perospirone on marble-burying behavior, which has been considered an animal model of obsessive-compulsive disorder (OCD), compared with the effects of other antipsychotics such as haloperidol and risperidone." | 3.73 | Perospirone, a novel antipsychotic drug, inhibits marble-burying behavior via 5-HT1A receptor in mice: implications for obsessive-compulsive disorder. ( Egashira, N; Fujiwara, M; Harada, S; Iwasaki, K; Matsushita, M; Mishima, K; Nishimura, R; Okuno, R, 2005) |
| "The anxiolytic effects of aniracetam have not been proven in animals despite its clinical usefulness for post-stroke anxiety." | 3.71 | Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism. ( Kurasawa, M; Nakamura, K, 2001) |
| "The effects of intra-amygdala injection of midazolam (20 nmol) and 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT; 8 and 16 nmol) were investigated in rats submitted to the elevated T-maze, a new animal model of anxiety." | 3.70 | Anxiolytic effect of intra-amygdala injection of midazolam and 8-hydroxy-2-(di-n-propylamino)tetralin in the elevated T-maze. ( Graeff, FG; Viana, MB; Zangrossi, H, 1999) |
| "Neonatal treatment with clomipramine induces behavioral alterations during adulthood that resemble symptoms observed in human depression." | 3.70 | Pharmacological features of masculine sexual behavior in an animal model of depression. ( Bonilla-Jaime, H; Retana-Marquez, S; Velazquez-Moctezuma, J, 1998) |
| "The present study determined the effect of pretreatment with "silent" selective 5-HT1A receptor antagonists on cholecystokinin (CCK)-mediated effects on rat behaviour in the elevated x-maze model of anxiety." | 3.69 | Attenuation of CCK-induced aversion in rats on the elevated x-maze by the selective 5-HT1A receptor antagonists (+) WAY100135 and WAY100635. ( Bickerdike, MJ; Fletcher, A; Marsden, CA, 1995) |
| "Depression is one of the most common neuropsychiatric disturbances in Parkinson's disease (PD), but its pathophysiology is not definite." | 1.56 | Involvement of the Dorsal Hippocampus 5-HT1A Receptors in the Regulation of Depressive-Like Behaviors in Hemiparkinsonian Rats. ( Guo, Y; Hu, W; Jiang, YF; La, XM; Liu, J; Wang, HS; Xie, W; Yang, J; Zhang, J; Zhang, L, 2020) |
| "Severe spinal cord contusions interrupt nearly all brain projections to lumbar circuits producing leg movement." | 1.48 | Cortico-reticulo-spinal circuit reorganization enables functional recovery after severe spinal cord contusion. ( Anderson, MA; Anil, S; Asboth, L; Barraud, Q; Batti, L; Baud, L; Beauparlant, J; Courtine, G; Friedli, L; Kreider, J; Martinez-Gonzalez, C; Pagès, S; Pidpruzhnykova, G; Rey, E; Schneider, BL; Shkorbatova, P, 2018) |
| "BALB/c mice were dosed intraperitoneally with 5, 15, 30, 40, or 50 mg/kg sarpogrelate 48, 24, and 0 hours prior to bright light exposure (10,000 lux) as well as 24 and 48 hours after exposure." | 1.42 | Sarpogrelate, a 5-HT2A Receptor Antagonist, Protects the Retina From Light-Induced Retinopathy. ( Coyner, AS; Datta, S; Gale, MJ; Ku, C; Nicholson, A; Pennesi, ME; Regis, D; Ryals, RC; Sinha, W; Tullis, BE; Wen, Y; Yang, P, 2015) |
| "Vortioxetine reversed PCPA-induced memory deficits dose-dependently with a minimal effective dose (MED) ≤0." | 1.40 | Vortioxetine dose-dependently reverses 5-HT depletion-induced deficits in spatial working and object recognition memory: a potential role for 5-HT1A receptor agonism and 5-HT3 receptor antagonism. ( du Jardin, KG; Jensen, JB; Pehrson, AL; Sanchez, C, 2014) |
| "Motor symptoms of Parkinson's disease are commonly treated using l-DOPA although long-term treatment usually causes debilitating motor side effects including dyskinesias." | 1.39 | Effects of 5-HT1A receptor stimulation on striatal and cortical M1 pERK induction by L-DOPA and a D1 receptor agonist in a rat model of Parkinson's disease. ( Bishop, C; Dupre, KB; Eskow Jaunarajs, KL; Goldenberg, AA; Lindenbach, D; Ostock, CY, 2013) |
| "Sepsis was induced by peripheral treatment with lipopolysaccharide (5 mg/kg) and circadian rhythms were monitored following recovery." | 1.38 | Long-lasting effects of sepsis on circadian rhythms in the mouse. ( Anderson, ST; Coogan, AN; Moynagh, PN; O'Callaghan, EK, 2012) |
| "Depression is a major health problem worldwide." | 1.38 | Selective siRNA-mediated suppression of 5-HT1A autoreceptors evokes strong anti-depressant-like effects. ( Alvarado, G; Artigas, F; Bortolozzi, A; Carmona, MC; Castañé, A; Cortés, R; Fernández, G; Ferrés-Coy, A; Montefeltro, A; Perales, JC; Santana, N; Semakova, J; Toth, M, 2012) |
| "Rats with experimental diabetes mellitus (DM) have been shown to have both bladder and urethral dysfunction during reflex voiding." | 1.38 | Improving voiding efficiency in the diabetic rat by a 5-HT1A serotonin receptor agonist. ( Andersson, KE; Gu, B; Si, J; Wu, G; Xu, Y, 2012) |
| "Depression is the most common psychiatric disorder in Huntington's disease (HD) patients." | 1.37 | Sexually dimorphic serotonergic dysfunction in a mouse model of Huntington's disease and depression. ( Chevarin, C; Du, X; Hannan, AJ; Lanfumey, L; Leang, L; Pang, TY; Renoir, T; Zajac, MS, 2011) |
| "Cervical incomplete spinal cord injuries often lead to severe and persistent impairments of sensorimotor functions and are clinically the most frequent type of spinal cord injury." | 1.37 | Motor deficits and recovery in rats with unilateral spinal cord hemisection mimic the Brown-Sequard syndrome. ( Filli, L; Schwab, ME; Weinmann, O; Zörner, B, 2011) |
| " Apomorphine and ± 8-OH-DPAT had an inhibiting effect on sexual behavior, but only females dosed with apomorphine showed a different response in avoiders and approachers, more inhibiting effect in avoiders than approachers." | 1.37 | A new female rat animal model for hypoactive sexual desire disorder; behavioral and pharmacological evidence. ( Chan, JS; de Jong, TR; Olivier, B; Oosting, RS; Snoeren, EM; Waldinger, MD, 2011) |
| "After complete spinal cord transections that removed all supraspinal inputs in adult rats, combinations of serotonergic agonists and epidural electrical stimulation were able to acutely transform spinal networks from nonfunctional to highly functional and adaptive states as early as 1 week after injury." | 1.35 | Transformation of nonfunctional spinal circuits into functional states after the loss of brain input. ( Ao, Y; Courtine, G; Edgerton, VR; Gerasimenko, Y; Ichiyama, RM; Lavrov, I; Musienko, P; Roy, RR; Sofroniew, MV; Song, B; van den Brand, R; Yew, A; Zhong, H, 2009) |
| " Furthermore, chronic administration of low doses of the 5-HT(1) agonists in combination was able to prevent development of dyskinesia, and reduce the up-regulation of FosB after daily treatment with l-DOPA in the rat 6-OHDA model." | 1.35 | Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia. ( Bezard, E; Björklund, A; Carlsson, T; Carta, M; Di Luca, M; Gardoni, F; Kirik, D; Li, Q; Marcello, E; Muñoz, A; Qin, C, 2008) |
| "Down syndrome is produced by the trisomy of chromosome 21." | 1.33 | Hypothermic responses to 8-OH-DPAT in the Ts65Dn mouse model of Down syndrome. ( Costa, AC; Scott-McKean, JJ; Stasko, MR, 2006) |
| " While typical antipsychotics are often switched to atypical agents when adverse effects become limiting, there is little preclinical information to support this strategy, both in terms of efficacy and side effects." | 1.32 | Combined treatment of quetiapine with haloperidol in animal models of antipsychotic effect and extrapyramidal side effects: comparison with risperidone and chlorpromazine. ( Matsuoka, N; Mutoh, S; Shirakawa, K; Tada, M, 2004) |
| "Treatment with amphetamine caused significant disruption of prepulse inhibition in SHR and WKY rats, but not SD rats." | 1.32 | Prepulse inhibition of acoustic startle in spontaneously hypertensive rats. ( van den Buuse, M, 2004) |
| "Depression is a multifactorial illness and genetic factors play a role in its etiology." | 1.32 | Behavioral, neurochemical, and electrophysiological characterization of a genetic mouse model of depression. ( Adrien, J; Bouali, S; Costentin, J; El Yacoubi, M; Hamon, M; Leroux-Nicollet, I; Naudon, L; Popa, D; Vaugeois, JM, 2003) |
| "Catalepsy was measured in rats using both the cross-legged position test and the bar test." | 1.31 | Repeated treatment with 8-OH-DPAT induces tolerance to its ability to produce the 5-HT1A behavioural syndrome, but not to its ability to attenuate haloperidol-induced catalepsy. ( Colpaert, FC; Kleven, MS; Koek, W; Prinssen, EP, 2000) |
| " Paroxetine, in combination with WAY 100635, attenuated the hypothermic effects of 8-OH-DPAT as early as 3 days, with a full reversal evident following 7 days, whereas paroxetine, although attenuating the hypothermic effects in OB group by day 7, only reversed it fully after 14 days." | 1.30 | Onset of the effects of the 5-HT1A antagonist, WAY-100635, alone, and in combination with paroxetine, on olfactory bulbectomy and 8-OH-DPAT-induced changes in the rat. ( Cryan, JF; Leonard, BE; McGrath, C; Norman, TR, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (1.80) | 18.7374 |
| 1990's | 28 (16.77) | 18.2507 |
| 2000's | 66 (39.52) | 29.6817 |
| 2010's | 66 (39.52) | 24.3611 |
| 2020's | 4 (2.40) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, H | 1 |
| Altenbach, RJ | 1 |
| Carr, TL | 1 |
| Chandran, P | 1 |
| Hsieh, GC | 1 |
| Lewis, LG | 1 |
| Manelli, AM | 1 |
| Milicic, I | 1 |
| Marsh, KC | 1 |
| Miller, TR | 1 |
| Strakhova, MI | 1 |
| Vortherms, TA | 1 |
| Wakefield, BD | 1 |
| Wetter, JM | 1 |
| Witte, DG | 1 |
| Honore, P | 1 |
| Esbenshade, TA | 1 |
| Brioni, JD | 1 |
| Cowart, MD | 1 |
| Gunia-Krzyżak, A | 1 |
| Żelaszczyk, D | 1 |
| Rapacz, A | 1 |
| Żesławska, E | 1 |
| Waszkielewicz, AM | 1 |
| Pańczyk, K | 1 |
| Słoczyńska, K | 1 |
| Pękala, E | 1 |
| Nitek, W | 1 |
| Filipek, B | 1 |
| Marona, H | 1 |
| Solinski, HJ | 1 |
| Dranchak, P | 1 |
| Oliphant, E | 1 |
| Gu, X | 1 |
| Earnest, TW | 1 |
| Braisted, J | 1 |
| Inglese, J | 1 |
| Hoon, MA | 1 |
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Liu, Y | 1 |
| Liu, J | 3 |
| Jiao, SR | 1 |
| Liu, X | 1 |
| Guo, Y | 3 |
| Zhang, J | 4 |
| Yang, J | 2 |
| Xie, W | 2 |
| Wang, HS | 2 |
| Zhang, L | 2 |
| Jiang, YF | 1 |
| Hu, W | 1 |
| La, XM | 1 |
| Rombolà, L | 1 |
| Scuteri, D | 1 |
| Watanabe, C | 1 |
| Sakurada, S | 1 |
| Hamamura, K | 1 |
| Sakurada, T | 1 |
| Tonin, P | 1 |
| Corasaniti, MT | 1 |
| Bagetta, G | 1 |
| Morrone, LA | 1 |
| Janikova, M | 1 |
| Mainerova, K | 1 |
| Vojtechova, I | 1 |
| Petrasek, T | 1 |
| Svoboda, J | 1 |
| Stuchlik, A | 1 |
| Liao, S | 1 |
| Lv, J | 1 |
| Zhou, J | 1 |
| Kalavagunta, PK | 1 |
| Shang, J | 1 |
| Sestile, CC | 1 |
| Maraschin, JC | 1 |
| Rangel, MP | 1 |
| Santana, RG | 1 |
| Zangrossi, H | 6 |
| Graeff, FG | 2 |
| Audi, EA | 1 |
| Cai, CY | 1 |
| Wu, HY | 2 |
| Luo, CX | 2 |
| Zhu, DY | 2 |
| Zhang, Y | 1 |
| Zhou, QG | 2 |
| Asboth, L | 1 |
| Friedli, L | 1 |
| Beauparlant, J | 1 |
| Martinez-Gonzalez, C | 1 |
| Anil, S | 1 |
| Rey, E | 1 |
| Baud, L | 1 |
| Pidpruzhnykova, G | 1 |
| Anderson, MA | 1 |
| Shkorbatova, P | 1 |
| Batti, L | 1 |
| Pagès, S | 1 |
| Kreider, J | 1 |
| Schneider, BL | 1 |
| Barraud, Q | 1 |
| Courtine, G | 2 |
| Sanku, RKK | 1 |
| John, JS | 1 |
| Salkovitz, M | 1 |
| Ilies, MA | 1 |
| Walker, EA | 1 |
| Verma, L | 1 |
| Agrawal, D | 1 |
| Jain, NS | 1 |
| Guo, J | 1 |
| Yan, B | 1 |
| Wang, F | 1 |
| Gao, QH | 1 |
| Zhang, XJ | 1 |
| Yu, GJ | 1 |
| Zeng, Y | 1 |
| Qiu, JF | 1 |
| Geng, Q | 1 |
| Han, Q | 1 |
| Wierońska, JM | 1 |
| Acher, FC | 1 |
| Sławińska, A | 1 |
| Gruca, P | 1 |
| Lasoń-Tyburkiewicz, M | 1 |
| Papp, M | 2 |
| Pilc, A | 1 |
| Strauss, CV | 1 |
| Vicente, MA | 2 |
| Fuss, J | 1 |
| Vogt, MA | 1 |
| Weber, KJ | 1 |
| Burke, TF | 1 |
| Gass, P | 1 |
| Hensler, JG | 1 |
| Audero, E | 1 |
| Mlinar, B | 1 |
| Baccini, G | 1 |
| Skachokova, ZK | 1 |
| Corradetti, R | 1 |
| Gross, C | 1 |
| Wang, CC | 1 |
| Lin, HC | 1 |
| Chan, YH | 1 |
| Gean, PW | 1 |
| Yang, YK | 1 |
| Chen, PS | 1 |
| du Jardin, KG | 1 |
| Jensen, JB | 1 |
| Sanchez, C | 2 |
| Pehrson, AL | 1 |
| Miyazaki, I | 1 |
| Asanuma, M | 1 |
| Murakami, S | 1 |
| Takeshima, M | 1 |
| Torigoe, N | 1 |
| Kitamura, Y | 1 |
| Miyoshi, K | 1 |
| Lindenbach, D | 1 |
| Dupre, KB | 3 |
| Eskow Jaunarajs, KL | 1 |
| Ostock, CY | 1 |
| Goldenberg, AA | 1 |
| Bishop, C | 2 |
| Almeida, PV | 1 |
| Trovo, MC | 1 |
| Tokumoto, AM | 1 |
| Pereira, AC | 1 |
| Padovan, CM | 1 |
| Schijven, D | 1 |
| Sousa, VC | 1 |
| Roelofs, J | 1 |
| Olivier, B | 4 |
| Olivier, JD | 1 |
| Yang, Y | 1 |
| Kuang, Y | 1 |
| Wang, S | 2 |
| Jiang, Y | 1 |
| Ding, Y | 1 |
| Ding, M | 1 |
| Hui, YP | 1 |
| Wang, T | 1 |
| Han, LN | 1 |
| Li, LB | 1 |
| Sun, YN | 1 |
| Qiao, HF | 1 |
| Zhang, QJ | 1 |
| Lucot, JB | 1 |
| Brame, RE | 1 |
| Garrett, TL | 1 |
| Pfadenhauer, EH | 1 |
| Kumar, A | 1 |
| Fick, DB | 1 |
| Helton, DR | 1 |
| Tucci, MC | 1 |
| Dvorkin-Gheva, A | 2 |
| Johnson, E | 1 |
| Cheon, P | 1 |
| Taji, L | 1 |
| Agarwal, A | 1 |
| Foster, J | 1 |
| Szechtman, H | 2 |
| Mineur, YS | 1 |
| Einstein, EB | 1 |
| Bentham, MP | 1 |
| Wigestrand, MB | 1 |
| Blakeman, S | 1 |
| Newbold, SA | 1 |
| Picciotto, MR | 1 |
| Nascimento, JO | 1 |
| Kikuchi, LS | 1 |
| de Bortoli, VC | 1 |
| Viana, MB | 3 |
| Brosda, J | 1 |
| Müller, N | 1 |
| Bert, B | 1 |
| Fink, H | 1 |
| Radocaj, T | 1 |
| Mustapic, S | 1 |
| Prkic, I | 1 |
| Stucke, AG | 1 |
| Hopp, FA | 1 |
| Stuth, EA | 1 |
| Zuperku, EJ | 1 |
| Llamosas, N | 1 |
| Bruzos-Cidón, C | 1 |
| Rodríguez, JJ | 1 |
| Ugedo, L | 1 |
| Torrecilla, M | 1 |
| Tullis, BE | 1 |
| Ryals, RC | 1 |
| Coyner, AS | 1 |
| Gale, MJ | 1 |
| Nicholson, A | 1 |
| Ku, C | 1 |
| Regis, D | 1 |
| Sinha, W | 1 |
| Datta, S | 1 |
| Wen, Y | 1 |
| Yang, P | 1 |
| Pennesi, ME | 1 |
| Cruz, AV | 1 |
| McCoy, AJ | 1 |
| Delaville, C | 1 |
| Gerber, CM | 1 |
| Eyring, KW | 1 |
| Walters, JR | 1 |
| Mitchell, E | 1 |
| Klein, SL | 1 |
| Argyropoulos, KV | 1 |
| Sharma, A | 1 |
| Chan, RB | 1 |
| Toth, JG | 1 |
| Barboza, L | 1 |
| Bavley, C | 1 |
| Bortolozzi, A | 3 |
| Chen, Q | 1 |
| Liu, B | 1 |
| Ingenito, J | 1 |
| Mark, W | 1 |
| Dudakov, J | 1 |
| Gross, S | 1 |
| Di Paolo, G | 1 |
| Artigas, F | 3 |
| van den Brink, M | 1 |
| Toth, M | 3 |
| Heydari, A | 1 |
| Davoudi, S | 1 |
| Sagalajev, B | 1 |
| Viisanen, H | 1 |
| Wei, H | 1 |
| Pertovaara, A | 1 |
| Samad, N | 3 |
| Yasmin, F | 1 |
| Haleem, DJ | 6 |
| Ohno, Y | 2 |
| Shimizu, S | 2 |
| Imaki, J | 2 |
| Ishihara, S | 2 |
| Sofue, N | 2 |
| Sasa, M | 2 |
| Kawai, Y | 2 |
| Cheng, JP | 2 |
| Hoffman, AN | 1 |
| Zafonte, RD | 2 |
| Kline, AE | 2 |
| Moraes, CL | 1 |
| Bertoglio, LJ | 1 |
| Carobrez, AP | 1 |
| Mo, J | 1 |
| Zhang, H | 1 |
| Yu, LP | 1 |
| Sun, PH | 1 |
| Jin, GZ | 1 |
| Zhen, X | 1 |
| dos Santos, L | 1 |
| de Macedo, CE | 1 |
| Andrade, TG | 2 |
| Eskow, KL | 1 |
| Barnum, CJ | 1 |
| Jabeen, B | 1 |
| Batool, F | 1 |
| Muñoz, A | 1 |
| Li, Q | 1 |
| Gardoni, F | 1 |
| Marcello, E | 1 |
| Qin, C | 1 |
| Carlsson, T | 1 |
| Kirik, D | 1 |
| Di Luca, M | 1 |
| Björklund, A | 1 |
| Bezard, E | 1 |
| Carta, M | 1 |
| Bambico, FR | 1 |
| Nguyen, NT | 1 |
| Gobbi, G | 1 |
| Matsuzaki, H | 2 |
| Izumi, T | 2 |
| Matsumoto, M | 2 |
| Togashi, H | 2 |
| Yamaguchi, T | 2 |
| Yoshida, T | 2 |
| Watanabe, M | 1 |
| Yoshioka, M | 2 |
| S N, U | 1 |
| J M, V | 1 |
| N S, J | 1 |
| P V, D | 1 |
| Grabiec, M | 1 |
| Turlejski, K | 1 |
| Djavadian, R | 1 |
| Gomes, KS | 1 |
| Nunes-De-Souza, RL | 1 |
| Gerasimenko, Y | 1 |
| van den Brand, R | 1 |
| Yew, A | 1 |
| Musienko, P | 1 |
| Zhong, H | 1 |
| Song, B | 1 |
| Ao, Y | 1 |
| Ichiyama, RM | 1 |
| Lavrov, I | 1 |
| Roy, RR | 1 |
| Sofroniew, MV | 1 |
| Edgerton, VR | 1 |
| Christianson, JP | 1 |
| Ragole, T | 1 |
| Amat, J | 1 |
| Greenwood, BN | 1 |
| Strong, PV | 1 |
| Paul, ED | 1 |
| Fleshner, M | 1 |
| Watkins, LR | 1 |
| Maier, SF | 1 |
| Mombereau, C | 1 |
| Gur, TL | 1 |
| Onksen, J | 1 |
| Blendy, JA | 1 |
| Paterson, NE | 1 |
| Hanania, T | 1 |
| Huang, XY | 1 |
| Ye, ML | 1 |
| Hu, Y | 1 |
| Wu, DL | 1 |
| Zhu, LJ | 1 |
| Miguel, TL | 1 |
| Pobbe, RL | 2 |
| Spiacci Junior, A | 1 |
| Zangrossi Junior, H | 1 |
| Depoortère, R | 1 |
| Auclair, AL | 1 |
| Bardin, L | 1 |
| Colpaert, FC | 3 |
| Vacher, B | 1 |
| Newman-Tancredi, A | 1 |
| Chan, JS | 2 |
| Snoeren, EM | 2 |
| Cuppen, E | 1 |
| Waldinger, MD | 3 |
| Oosting, RS | 2 |
| Horinouchi, T | 1 |
| Boku, S | 1 |
| Inoue, T | 1 |
| Miwa, S | 1 |
| Koyama, T | 1 |
| Charkhpour, M | 1 |
| Nayebi, AR | 1 |
| Doustar, Y | 1 |
| Hassanzadeh, K | 1 |
| de Jong, TR | 2 |
| Rogel-Salazar, G | 1 |
| López-Rubalcava, C | 3 |
| Albelda, N | 1 |
| Joel, D | 1 |
| Filli, L | 1 |
| Zörner, B | 1 |
| Weinmann, O | 1 |
| Schwab, ME | 1 |
| Renoir, T | 2 |
| Zajac, MS | 1 |
| Du, X | 1 |
| Pang, TY | 2 |
| Leang, L | 1 |
| Chevarin, C | 2 |
| Lanfumey, L | 2 |
| Hannan, AJ | 2 |
| Gu, B | 1 |
| Wu, G | 1 |
| Si, J | 1 |
| Xu, Y | 1 |
| Andersson, KE | 1 |
| Schneider, A | 1 |
| Teschendorf, P | 1 |
| Vogel, P | 1 |
| Russ, N | 1 |
| Knapp, J | 1 |
| Böttiger, BW | 1 |
| Popp, E | 1 |
| Castañé, A | 2 |
| Semakova, J | 1 |
| Santana, N | 2 |
| Alvarado, G | 1 |
| Cortés, R | 2 |
| Ferrés-Coy, A | 2 |
| Fernández, G | 1 |
| Carmona, MC | 2 |
| Perales, JC | 1 |
| Montefeltro, A | 2 |
| Jakovcevski, M | 1 |
| Schachner, M | 1 |
| Morellini, F | 1 |
| Shanahan, NA | 1 |
| Velez, LP | 1 |
| Masten, VL | 1 |
| Dulawa, SC | 1 |
| West, CH | 1 |
| Boss-Williams, KA | 1 |
| Weiss, JM | 1 |
| Nahimi, A | 1 |
| Høltzermann, M | 1 |
| Landau, AM | 1 |
| Simonsen, M | 1 |
| Jakobsen, S | 1 |
| Alstrup, AK | 1 |
| Vang, K | 1 |
| Møller, A | 1 |
| Wegener, G | 1 |
| Gjedde, A | 1 |
| Doudet, DJ | 1 |
| Costa, L | 1 |
| Spatuzza, M | 1 |
| D'Antoni, S | 1 |
| Bonaccorso, CM | 1 |
| Trovato, C | 1 |
| Musumeci, SA | 1 |
| Leopoldo, M | 1 |
| Lacivita, E | 1 |
| Catania, MV | 1 |
| Ciranna, L | 1 |
| Tajiri, M | 1 |
| Hayata-Takano, A | 1 |
| Seiriki, K | 1 |
| Ogata, K | 1 |
| Hazama, K | 1 |
| Shintani, N | 1 |
| Baba, A | 2 |
| Hashimoto, H | 1 |
| Mo, C | 1 |
| Chan, G | 1 |
| O'Callaghan, EK | 1 |
| Anderson, ST | 1 |
| Moynagh, PN | 1 |
| Coogan, AN | 1 |
| Alkhatib, AH | 1 |
| Ganzer, PD | 1 |
| Moxon, KA | 1 |
| Knudsen, EB | 1 |
| Shumsky, JS | 1 |
| Olvera-Hernández, S | 1 |
| Chavira, R | 1 |
| Fernández-Guasti, A | 4 |
| Yohrling IV, GJ | 1 |
| Jiang, GC | 1 |
| DeJohn, MM | 1 |
| Robertson, DJ | 1 |
| Vrana, KE | 1 |
| Cha, JH | 1 |
| Lapiz, MD | 1 |
| Fulford, A | 1 |
| Muchimapura, S | 1 |
| Mason, R | 1 |
| Parker, T | 1 |
| Marsden, CA | 2 |
| van Kuyck, K | 1 |
| Demeulemeester, H | 2 |
| Feys, H | 2 |
| De Weerdt, W | 2 |
| Dewil, M | 1 |
| Tousseyn, T | 1 |
| De Sutter, P | 2 |
| Gybels, J | 2 |
| Bogaerts, K | 1 |
| Dom, R | 1 |
| Nuttin, B | 2 |
| May, JA | 1 |
| McLaughlin, MA | 1 |
| Sharif, NA | 1 |
| Hellberg, MR | 1 |
| Dean, TR | 1 |
| El Yacoubi, M | 2 |
| Bouali, S | 1 |
| Popa, D | 2 |
| Naudon, L | 2 |
| Leroux-Nicollet, I | 2 |
| Hamon, M | 1 |
| Costentin, J | 2 |
| Adrien, J | 2 |
| Vaugeois, JM | 2 |
| Sena, LM | 1 |
| Bueno, C | 1 |
| Gartside, SE | 1 |
| Johnson, DA | 1 |
| Leitch, MM | 1 |
| Troakes, C | 1 |
| Ingram, CD | 1 |
| Shayit, M | 1 |
| Yadid, G | 1 |
| Overstreet, DH | 3 |
| Weller, A | 1 |
| Osei-Owusu, P | 1 |
| Scrogin, KE | 1 |
| Tada, M | 1 |
| Shirakawa, K | 1 |
| Matsuoka, N | 1 |
| Mutoh, S | 1 |
| Ulloa, RE | 1 |
| Nicolini, H | 1 |
| van den Buuse, M | 1 |
| Ramos, AJ | 1 |
| Rubio, MD | 1 |
| Defagot, C | 1 |
| Hischberg, L | 1 |
| Villar, MJ | 1 |
| Brusco, A | 1 |
| Carey, RJ | 1 |
| DePalma, G | 1 |
| Damianopoulos, E | 1 |
| Shanahan, A | 1 |
| Müller, CP | 1 |
| Huston, JP | 1 |
| Mignon, LJ | 1 |
| Wolf, WA | 2 |
| Tomiyama, M | 1 |
| Kimura, T | 1 |
| Maeda, T | 1 |
| Kannari, K | 1 |
| Matsunaga, M | 1 |
| Baba, M | 1 |
| Agrati, D | 1 |
| Zuluaga, MJ | 1 |
| Uriarte, N | 1 |
| Pereira, M | 1 |
| Ferreira, A | 1 |
| Estrada-Camarena, E | 2 |
| Borelli, KG | 1 |
| Gárgaro, AC | 1 |
| dos Santos, JM | 1 |
| Brandão, ML | 1 |
| Pattij, T | 1 |
| Uitterdijk, A | 1 |
| Veening, JG | 1 |
| Cools, AR | 1 |
| van der Graaf, PH | 1 |
| Matsushita, M | 1 |
| Egashira, N | 1 |
| Harada, S | 1 |
| Okuno, R | 1 |
| Mishima, K | 1 |
| Iwasaki, K | 1 |
| Nishimura, R | 1 |
| Fujiwara, M | 1 |
| Picazo, O | 1 |
| Hernandez-Aragon, A | 1 |
| Tai, C | 1 |
| Miscik, CL | 1 |
| Ungerer, TD | 1 |
| Roppolo, JR | 1 |
| de Groat, WC | 1 |
| Stasko, MR | 1 |
| Scott-McKean, JJ | 1 |
| Costa, AC | 1 |
| Bekku, N | 1 |
| Yoshimura, H | 1 |
| Araki, H | 1 |
| Landry, ES | 1 |
| Lapointe, NP | 2 |
| Rouillard, C | 1 |
| Levesque, D | 1 |
| Hedlund, PB | 1 |
| Guertin, PA | 2 |
| Laengle, UW | 1 |
| Trendelenburg, AU | 1 |
| Markstein, R | 1 |
| Nogues, V | 1 |
| Provencher-Bollinger, A | 1 |
| Roman, D | 1 |
| Ba, M | 1 |
| Kong, M | 1 |
| Ma, G | 1 |
| Yang, H | 1 |
| Lu, G | 1 |
| Chen, S | 1 |
| Liu, Z | 1 |
| Wagner, AK | 1 |
| Westergom, BP | 1 |
| Malena, RR | 1 |
| Olsen, AS | 1 |
| Sozda, CN | 1 |
| Luthra, P | 1 |
| Panda, M | 1 |
| Aslam, HA | 1 |
| Mignon, L | 1 |
| Curran, AK | 1 |
| Leiter, JC | 2 |
| Berrocoso, E | 1 |
| De Benito, MD | 1 |
| Mico, JA | 1 |
| Toppin, VA | 1 |
| Harris, MB | 1 |
| Kober, AM | 1 |
| St-John, WM | 1 |
| Kim, DS | 1 |
| Kim, JE | 1 |
| Kwak, SE | 1 |
| Kim, DW | 1 |
| Choi, SY | 1 |
| Kwon, OS | 1 |
| Kang, TC | 1 |
| Hildreth, CM | 1 |
| Padley, JR | 1 |
| Pilowsky, PM | 1 |
| Goodchild, AK | 1 |
| Salazar-Colocho, P | 1 |
| Del Río, J | 1 |
| Frechilla, D | 1 |
| Khan, A | 1 |
| Perveen, T | 1 |
| Haider, S | 1 |
| Abdul Haleem, M | 1 |
| Léna, C | 1 |
| Alexandre, C | 1 |
| Suzuki, M | 1 |
| Matsuda, T | 1 |
| Somboonthum, P | 1 |
| Asano, S | 1 |
| Takuma, K | 1 |
| Nogi, H | 1 |
| Korte, SM | 1 |
| Buwalda, B | 1 |
| Meijer, O | 1 |
| De Kloet, ER | 1 |
| Bohus, B | 1 |
| Compagnon, P | 1 |
| Ernouf, D | 1 |
| Narcisse, G | 1 |
| Daoust, M | 1 |
| Shepherd, JK | 1 |
| Grewal, SS | 1 |
| Fletcher, A | 2 |
| Bill, DJ | 1 |
| Dourish, CT | 2 |
| Klint, T | 1 |
| Andersson, G | 1 |
| Janowsky, DS | 2 |
| Pucilowski, O | 1 |
| Rezvani, AH | 1 |
| Handley, SL | 1 |
| McBlane, JW | 1 |
| Grignaschi, G | 1 |
| Mantelli, B | 1 |
| Samanin, R | 1 |
| Bickerdike, MJ | 1 |
| Coudereau, JP | 1 |
| Monier, C | 1 |
| Frances, H | 1 |
| Przegaliński, E | 1 |
| Moryl, E | 1 |
| Fujiwara, T | 1 |
| Chiba, S | 1 |
| Lahmame, A | 1 |
| Armario, A | 1 |
| Daws, LC | 1 |
| Schiller, GD | 1 |
| Orbach, J | 1 |
| Bonilla-Jaime, H | 1 |
| Retana-Marquez, S | 1 |
| Velazquez-Moctezuma, J | 1 |
| Cryan, JF | 2 |
| McGrath, C | 2 |
| Leonard, BE | 3 |
| Norman, TR | 2 |
| Gerber, K | 2 |
| Filakovszky, J | 2 |
| Halasz, P | 1 |
| Bagdy, G | 3 |
| Ogren, SO | 1 |
| Misane, I | 1 |
| Harkin, A | 1 |
| Kelly, JP | 1 |
| McNamara, M | 1 |
| Connor, TJ | 1 |
| Dredge, K | 1 |
| Redmond, A | 1 |
| Duxon, MS | 1 |
| Starr, KR | 1 |
| Upton, N | 1 |
| Bruins Slot, LA | 1 |
| Koek, W | 2 |
| Dupuis, DS | 1 |
| Prinssen, EP | 1 |
| Kleven, MS | 1 |
| Cheeta, S | 1 |
| Kenny, PJ | 1 |
| File, SE | 1 |
| Kantor, S | 1 |
| Graf, M | 1 |
| Anheuer, ZE | 1 |
| Nakamura, K | 1 |
| Kurasawa, M | 1 |
| Goris, I | 1 |
| Zwaenepoel, I | 1 |
| Plets, C | 1 |
| Kaur, G | 1 |
| Kulkarni, SK | 1 |
| Shirayama, Y | 1 |
| Muneoka, KT | 1 |
| Takigawa, M | 1 |
| Minabe, Y | 1 |
| Kostowski, W | 1 |
| Dyr, W | 1 |
| Krzascik, P | 1 |
| Järbe, T | 1 |
| Archer, T | 1 |
| Engleman, EA | 1 |
| Murphy, JM | 1 |
| Zhou, FC | 1 |
| Hingtgen, JN | 1 |
| Yadin, E | 1 |
| Friedman, E | 1 |
| Bridger, WH | 1 |
| Wong, DT | 1 |
| Threlkeld, PG | 1 |
| Lumeng, L | 1 |
| Li, TK | 1 |
| Waeber, C | 1 |
| Dietl, MM | 1 |
| Hoyer, D | 1 |
| Palacios, JM | 1 |
| Kennett, GA | 1 |
| Curzon, G | 1 |
| Löscher, W | 1 |
| Czuczwar, SJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Study on Preliminary Safety and Efficacy of the ARC Therapy Using the ARC-IM Lumbar System to Support Mobility in People With Chronic Spinal Cord Injury[NCT05942339] | 8 participants (Anticipated) | Interventional | 2023-08-31 | Not yet recruiting | |||
| Role of Sleep Homeostasis in the Development of the L-Dopa Induced Dyskinesias in Patients With Parkinson's Disease[NCT02200887] | 48 participants (Actual) | Observational | 2013-09-30 | Completed | |||
| STIMO-PARKINSON: Study on Feasibility of Targeted Epidural Spinal Stimulation (TESS) to Improve Mobility in Patients With Parkinson's Disease[NCT04956770] | 2 participants (Actual) | Interventional | 2021-06-14 | Active, not recruiting | |||
| Restoring Hemodynamic Stability Using Targeted Epidural Spinal Stimulation Following Spinal Cord Injury[NCT04994886] | 8 participants (Anticipated) | Interventional | 2021-06-08 | Recruiting | |||
| Restoring Hemodynamic Stability Using Targeted Epidural Spinal Stimulation Following Spinal Cord Injury[NCT05044923] | 8 participants (Anticipated) | Interventional | 2021-12-31 | Recruiting | |||
| Epidural Electrical Stimulation to Restore Hemodynamic Stability and Trunk Control in People With Spinal Cord Injury[NCT05111093] | 20 participants (Anticipated) | Interventional | 2021-11-29 | Recruiting | |||
| Priming With High-Frequency Trans-spinal Stimulation to Augment Locomotor Benefits in Spinal Cord Injury[NCT04807764] | 45 participants (Anticipated) | Interventional | 2021-08-01 | Recruiting | |||
| A Randomized, Placebo-Controlled Pilot Study in Huntington's Disease (CIT-HD)[NCT00271596] | Phase 2 | 33 participants (Actual) | Interventional | 2005-11-30 | Completed | ||
| Tri-therapy (SPINALON)-Elicited Spinal Locomotor Network Activation: Phase I-IIa Clinical Trial in Patients With Chronic Spinal Cord Injury[NCT01484184] | Phase 1/Phase 2 | 50 participants (Actual) | Interventional | 2013-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Full Scale Name: The Executive Composite Score (ECS). Definition: Subscales were averaged to compute this composite total score. The ECS is the weighted average of performance on 6 subtests of executive function, including (1) the Controlled Oral Word Association Test, (2) Symbol Digit Modalities test; (3) Stroop Color Word Test (Interference Trial), (4) Trail Making test (Part B), (5) Letter-Number Sequencing, and (6) Animal Naming. Construct Measured: Thinking tasks involving planning, working memory, attention, problem solving, verbal reasoning, inhibition, mental flexibility, and task switching. ECS Scale Range: The ECS score ranges from -5 to +5 on a standardized (Z) score scale, where lower scores indicate poorer performance on executive functioning tasks. Change Calculation Details: Compares change in executive functioning performance from visit 2 (week 0) to the weighted average of visits 5 (week 12) & 6 (week 15) for the citalopram versus placebo cohort. (NCT00271596)
Timeframe: after 15 weeks of treatment
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Citalopram | 0.005 |
| Placebo | 0.172 |
Full Scale Name: Hamilton Rating Scale for Depression (HAM-D). Definition: The Hamilton Rating Scale for Depression is a clinician-administered multiple item questionnaire used to provide an indication of depression. Construct Measured: Depression. HAM-D Score Range: Raw scores may range from 0 to 54, where higher scores indicate worsening mood. Change Calculation Details: Compares change in mood from screening (intake visit) to visit 6 (week 15) for the citalopram versus placebo cohort. (NCT00271596)
Timeframe: after 15 weeks of treatment
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Citalopram | -0.67 |
| Placebo | 1.23 |
Full Scale Name: Letter Number Sequencing (LNS) subtest from the Wechsler Adult Intelligence Scale (WAIS) third edition. Definition: LNS is a task that requires the reordering of an initially unordered set of letters and numbers. Construct Measured: Working memory. LNS Score Range: Raw scores may range from 0 to 21, where lower scores indicate poorer performance in working memory. Change Calculation Details: Compares change in working memory performance from visit 2 (week 0) to the weighted average of visits 5 (week 12) & 6 (week 15) for the citalopram versus placebo cohort. (NCT00271596)
Timeframe: after 15 weeks of treatment
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Citalopram | -0.113 |
| Placebo | 0.225 |
Semantic Fluency Score. Definition: The Semantic Fluency Score is the number of words a person can produce given a category, including naming (1) Animal names, (2) Fruit names, (3) Boy names, (4) Girl names, and (5) Vegetable names. Construct Measured: Working memory and verbal initiation. Scale Range: The Semantic Fluency Score ranges from -5 to +5 on a standardized (Z) score scale, where lower scores indicate poorer performance on working memory tasks. Change Calculation Details: Compares change in working memory performance from visit 2 (week 0) where patients named fruit names to the weighted average of visits 5 (week 12) & 6 (week 15) where patients named girl names and vegetable names respectively for the citalopram versus placebo cohort. (NCT00271596)
Timeframe: after 15 weeks of treatment
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Citalopram | 0.386 |
| Placebo | 0.664 |
"Full Scale Name: Stroop Interference subtest from The Stroop Color and Word Test. Definition: Participants are asked to name the ink color in which a word is printed when the word itself (which is irrelevant to the task) is the name of a different color rather than the same color. For example, participants may be asked to say red to the word blue printed in red ink. Constructs Measured: Selective attention, response inhibition, cognitive flexibility, and processing speed. Scale Range: The Stroop Interference score ranges from -5 to +5 on a standardized (Z) score scale, where lower scores indicate poorer performance. Change Calculation Details: Compares change in attention and processing speed performance from visit 2 (week 0) to the weighted average of visits 5 (week 12) and 6 (week 15) for the citalopram versus placebo cohort." (NCT00271596)
Timeframe: after 15 weeks of treatment
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Citalopram | -0.256 |
| Placebo | -0.046 |
Full Scale Name: Hamilton Rating Scale for Depression (HAM-D). Definition: The Hamilton Rating Scale for Depression is a clinician-administered multiple item questionnaire used to provide an indication of depression. Construct Measured: Depression. HAM-D Score Range: Raw scores may range from 0 to 54, where higher scores indicate worsening mood. Change Calculation Details: This analysis was restricted to a subgroup and, accordingly, does not reflect the total number of participants as reported in the Participant Flow. This analysis compares change in mood from screening (intake visit) to visit 6 (week 15) for the citalopram versus placebo cohort. (NCT00271596)
Timeframe: after 15 weeks of treatment
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Citalopram | -0.10 |
| Placebo | 1.50 |
Full Scale Name: The Symbol Digit Modalities Test (SDMT). Definition: The SDMT screens for organic cerebral dysfunction by having the examinee use a reference key to pair specific numbers with given geometric figures in 90 seconds. Construct Measured: Attention, processing speed, and working memory. SDMT Scale Range: Raw scores may range from 0 to 110, where lower scores indicate poorer performance. Change Calculation Details: Compares change in performance from visit 2 (week 0) to the weighted average of visits 5 (week 12) & 6 (week 15) for the citalopram versus placebo cohort. (NCT00271596)
Timeframe: after 15 weeks of treatment
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Citalopram | -0.227 |
| Placebo | -0.170 |
Full Scale Name: The Total Functional Capacity (TFC) subscale from the Unified Huntington's Disease Rating Scale (UHDRS). Definition: The TFC is a score that classifies five stages of Huntington's Disease and five levels of function in the domains of workplace, finances, domestic chores, activities of daily living and requirements for unskilled or skilled care. Construct Measured: Activities of Daily Living. Scale Range: The TFC score ranges from 0 to 13, where lower scores indicate poorer performance in activities of daily living. Change Calculation Details: Compares change in TFC performance from Baseline (week -4) to the weighted average of visits 4 (week 6) and 6 (week 15) for the citalopram versus placebo cohort. (NCT00271596)
Timeframe: after 15 weeks of treatment
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Citalopram | -0.54 |
| Placebo | -0.06 |
"Full Scale Name: Trail Making Test Part B (TMT-B). Definition: The TMT-B test requires participants to connect-the-dots of 25 consecutive targets on a sheet of paper where the subject alternates between numbers and letters, going in both numerical and alphabetical order. Constructs Measured: Attention, set shifting, and processing speed. Scale range: The TMT-B score ranges from -5 to +5 on a standardized (Z) score scale, where lower scores indicate poorer performance. Change Calculation Details: Compares change in attention and processing speed performance from visit 2 (week 0) to the weighted average of visits 5 (week 12) and 6 (week 15) for the citalopram versus placebo cohort." (NCT00271596)
Timeframe: after 15 weeks of treatment
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Citalopram | 0.087 |
| Placebo | 0.405 |
Full Scale Name: The Verbal Fluency Score (VFC). Definition: The VFC is the number of words a person can produce given a letter, including (1) Naming words that start with F, A, and S; (2) naming words that start with K, W, and R; (3) naming words that start with V, I, and P; (4) naming words that start with O, G, and B; (5) naming words that start with E, N, and T; and (6) naming words that start with J, C, and S. Construct Measured: Verbal initiation and flexibility. Scale Range: The Verbal Fluency Composite Score ranges from -5 to +5 on a standardized (Z) score scale, where lower scores indicate poorer performance. Change Calculation Details: Compares change in verbal initiation and flexibility from visit 2 (week 0) where patients named words starting with O, G, and B to the weighted average of visits 5 (week 12) and 6 (week 15) where patients named words starting with E, N, and T, and J, C, and S respectively for the citalopram versus placebo cohort. (NCT00271596)
Timeframe: after 15 weeks of treatment
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Citalopram | 0.140 |
| Placebo | 0.071 |
4 reviews available for 8-hydroxy-2-(di-n-propylamino)tetralin and Disease Models, Animal
| Article | Year |
|---|---|
Animal models of obsessive-compulsive disorder: exploring pharmacology and neural substrates.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Deep Brain Stimulation; Disease Models, Animal; Dop | 2012 |
Serotonin in animal models of alcoholism.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Alcoholism; Animals; Disease Models, Animal; Male; Mice; Rat | 1993 |
Serotonin mechanisms in animal models of anxiety.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Anti-Anxiety Agents; Anxiety; Buspirone; Disease Mo | 1993 |
Hippocampal and septal injections of nicotine and 8-OH-DPAT distinguish among different animal tests of anxiety.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Anxiety Disorders; Disease Models, Animal; Hippocam | 2000 |
163 other studies available for 8-hydroxy-2-(di-n-propylamino)tetralin and Disease Models, Animal
| Article | Year |
|---|---|
cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain responses against carrageenan-induced hyperalgesia.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzofurans; Carrageenan; Disease Models, Animal; | 2008 |
Structure-anticonvulsant activity studies in the group of (E)-N-cinnamoyl aminoalkanols derivatives monosubstituted in phenyl ring with 4-Cl, 4-CH
Topics: Amino Alcohols; Animals; Anticonvulsants; Crystallography, X-Ray; Disease Models, Animal; Dose-Respo | 2017 |
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
Topics: Animals; Behavior, Animal; Cell-Free System; Dermatitis, Contact; Disease Models, Animal; Ganglia, S | 2019 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
Serotonin
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Disease Models, Animal; Dopamine; Habituation, Psyc | 2019 |
Involvement of the Dorsal Hippocampus 5-HT1A Receptors in the Regulation of Depressive-Like Behaviors in Hemiparkinsonian Rats.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Amygdala; Animals; Behavior, Animal; Depression; Disease Mod | 2020 |
Role of 5-HT1A Receptor in the Anxiolytic-Relaxant Effects of Bergamot Essential Oil in Rodent.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Anti-Anxiety Agents; Anxiety; Behavior, Animal; Dis | 2020 |
Memantine and Riluzole Exacerbate, Rather Than Ameliorate Behavioral Deficits Induced by 8-OH-DPAT Sensitization in a Spatial Task.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Behavior, Animal; Disease Models, Animal; Male; Mem | 2021 |
Effects of two chronic stresses on mental state and hair follicle melanogenesis in mice.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Behavior, Animal; Cell Line, Tumor; Cell Proliferat | 2017 |
B2-kinin receptors in the dorsal periaqueductal gray are implicated in the panicolytic-like effect of opiorphin.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Bradykinin; Bradykinin B2 Receptor Antagonists; Dis | 2017 |
Extracellular regulated protein kinaseis critical for the role of 5-HT1a receptor in modulating nNOS expression and anxiety-related behaviors.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Animals, Newborn; Anxiety; Dark Adaptation; Disease | 2019 |
Cortico-reticulo-spinal circuit reorganization enables functional recovery after severe spinal cord contusion.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Brain; Channelrhodopsins; Disease Models, Animal; F | 2018 |
Potential learning and memory disruptors and enhancers in a simple, 1-day operant task in mice.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Adjuvants, Anesthesia; Animals; Conditioning, Operant; Disea | 2018 |
Enhanced central histaminergic transmission attenuates compulsive-like behavior in mice.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Compulsive Behavior; Disease Models, Animal; Dose-R | 2018 |
[Establishment of a rat model of premature ejaculation with 8-OH-DPAT].
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Benzoic Acid; Disease Models, Animal; Ejaculation; | 2018 |
The antipsychotic-like effects of the mGlu group III orthosteric agonist, LSP1-2111, involves 5-HT₁A signalling.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Aminobutyrates; Amphetamines; Animals; Antipsychotic Agents; | 2013 |
Activation of 5-HT1A receptors in the rat basolateral amygdala induces both anxiolytic and antipanic-like effects.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Amygdala; Animals; Anti-Anxiety Agents; Anxiety; Dark Adapta | 2013 |
Hippocampal serotonin-1A receptor function in a mouse model of anxiety induced by long-term voluntary wheel running.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Anxiety; Disease Models, Animal; Hippocampus; Mice; | 2013 |
Suppression of serotonin neuron firing increases aggression in mice.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Action Potentials; Aggression; Animals; Anxiety; Autoradiogr | 2013 |
5-HT1A-receptor agonist modified amygdala activity and amygdala-associated social behavior in a valproate-induced rat autism model.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Amygdala; Animals; Autistic Disorder; Behavior, Animal; Cina | 2013 |
Vortioxetine dose-dependently reverses 5-HT depletion-induced deficits in spatial working and object recognition memory: a potential role for 5-HT1A receptor agonism and 5-HT3 receptor antagonism.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Benzamides; Disease Models, Animal; Dose-Response R | 2014 |
Targeting 5-HT(1A) receptors in astrocytes to protect dopaminergic neurons in Parkinsonian models.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Adrenergic Agents; Animals; Astrocytes; Brain; Buspirone; Ce | 2013 |
Effects of 5-HT1A receptor stimulation on striatal and cortical M1 pERK induction by L-DOPA and a D1 receptor agonist in a rat model of Parkinson's disease.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Corpus Striatum; Disease Models, Animal; Extracellu | 2013 |
Role of serotonin 1A receptors in the median raphe nucleus on the behavioral consequences of forced swim stress.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Behavior, Animal; Disease Models, Animal; Hippocamp | 2013 |
Serotonin 1A receptors and sexual behavior in a genetic model of depression.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Brain; Depressive Disorder, Major; Disease Models, | 2014 |
Serotonin 1A receptor inhibits the status epilepticus induced by lithium-pilocarpine in rats.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Action Potentials; Analysis of Variance; Animals; Disease Mo | 2014 |
Anxiolytic effects of prelimbic 5-HT(1A) receptor activation in the hemiparkinsonian rat.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Anti-Anxiety Agents; Anxiety; Disease Models, Anima | 2015 |
The broad-spectrum antiemetic effects ETI-385 result from stimulation of 5-HT1A and 5-HT1D receptors.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antiemetics; Cats; Disease Models, Animal; Dose-Res | 2014 |
Performance of compulsive behavior in rats is not a unitary phenomenon - validation of separate functional components in compulsive checking behavior.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Compulsive Behavior; Disease Models, Animal; Male; | 2014 |
Expression of the 5-HT1A serotonin receptor in the hippocampus is required for social stress resilience and the antidepressant-like effects induced by the nicotinic partial agonist cytisine.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Alkaloids; Animals; Antidepressive Agents; Azocines; Disease | 2015 |
Dorsomedial hypothalamus serotonin 1A receptors mediate a panic-related response in the elevated T-maze.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Analysis of Variance; Animals; Avoidance Learning; Disease M | 2014 |
Modulatory Role of Postsynaptic 5-Hydroxytryptamine Type 1A Receptors in (±)-8-Hydroxy-N,N-dipropyl-2-aminotetralin-Induced Hyperphagia in Mice.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Aging; Animals; Disease Models, Animal; Dose-Response Relati | 2015 |
Activation of 5-HT1A receptors in the preBötzinger region has little impact on the respiratory pattern.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Action Potentials; Analysis of Variance; Animals; Disease Mo | 2015 |
Deletion of GIRK2 Subunit of GIRK Channels Alters the 5-HT1A Receptor-Mediated Signaling and Results in a Depression-Resistant Behavior.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Action Potentials; Animals; Antidepressive Agents, Second-Ge | 2015 |
Sarpogrelate, a 5-HT2A Receptor Antagonist, Protects the Retina From Light-Induced Retinopathy.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Disease Models, Animal; Electroretinography; Inject | 2015 |
Effects of L-dopa priming on cortical high beta and high gamma oscillatory activity in a rodent model of Parkinson's disease.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Benzazepines; Disease Models, Animal; Dopamine Agon | 2016 |
Behavioural traits propagate across generations via segregated iterative-somatic and gametic epigenetic mechanisms.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Anxiety; Behavior, Animal; Disease Models, Animal; | 2016 |
The effect of sertraline and 8-OH-DPAT on the PTZ_induced seizure threshold: Role of the nitrergic system.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Analysis of Variance; Animals; Convulsants; Disease Models, | 2017 |
Descending antinociception induced by secondary somatosensory cortex stimulation in experimental neuropathy: role of the medullospinal serotonergic pathway.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Action Potentials; Animals; Disease Models, Animal; Electric | 2017 |
Co-treatment with imipramine averted haloperidol-instigated tardive dyskinesia: Association with serotonin in brain regions.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Behavior, Animal; Brain; Disease Models, Animal; Ha | 2016 |
Anticataleptic 8-OH-DPAT preferentially counteracts with haloperidol-induced Fos expression in the dorsolateral striatum and the core region of the nucleus accumbens.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Behavior, Animal; Catalepsy; Corpus Striatum; Disea | 2008 |
A delayed and chronic treatment regimen with the 5-HT1A receptor agonist 8-OH-DPAT after cortical impact injury facilitates motor recovery and acquisition of spatial learning.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Analysis of Variance; Animals; Behavior, Animal; Brain Injur | 2008 |
Interplay between glutamate and serotonin within the dorsal periaqueductal gray modulates anxiety-related behavior of rats exposed to the elevated plus-maze.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Analysis of Variance; Animals; Anxiety; Behavior, Animal; Di | 2008 |
L-stepholidine reduced L-DOPA-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Analysis of Variance; Animals; Antiparkinson Agents; Antipsy | 2010 |
Involvement of median raphe nucleus 5-HT1A receptors in the regulation of generalized anxiety-related defensive behaviours in rats.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Anxiety; Avoidance Learning; Behavior, Animal; Dise | 2008 |
Striatal 5-HT1A receptor stimulation reduces D1 receptor-induced dyskinesia and improves movement in the hemiparkinsonian rat.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Adrenergic Agents; Animals; Benzazepines; Biogenic Monoamine | 2008 |
Desensitization of pre and post synaptic 5-HT-1A receptor responses following long term consumption of sugar rich diet: implications for sugar-induced obesity.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Behavior, Animal; Body Weight; Brain; Dietary Sucro | 2008 |
Serotonin(1A) receptor agonism in the expression of behavioral dopaminergic supersensitivity in subchronic haloperidol treated rats.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Basal Ganglia Diseases; Behavior, Animal; Brain; Di | 2008 |
Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antip | 2008 |
Decline in serotonergic firing activity and desensitization of 5-HT1A autoreceptors after chronic unpredictable stress.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Action Potentials; Analysis of Variance; Animals; Chronic Di | 2009 |
Early postnatal stress affects 5-HT1A receptor function in the medial prefrontal cortex in adult rats.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Aging; Animals; Animals, Newborn; Behavior, Animal; Disease | 2009 |
Neurosteroids modulate compulsive and persistent behavior in rodents: implications for obsessive-compulsive disorder.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Analysis of Variance; Animals; Behavior, Animal; Dehydroepia | 2009 |
Reduction of the number of new cells reaching olfactory bulbs impairs olfactory perception in the adult opossum.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Bromodeoxyuridine; Buspirone; Cell Count; Cues; Dis | 2009 |
Implication of the 5-HT2A and 5-HT2C (but not 5HT1A) receptors located within the periaqueductal gray in the elevated plus-maze test-retest paradigm in mice.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Amphetamines; Analysis of Variance; Animals; Anxiety; Behavi | 2009 |
Transformation of nonfunctional spinal circuits into functional states after the loss of brain input.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Analysis of Variance; Animals; Biomechanical Phenomena; Brai | 2009 |
Transformation of nonfunctional spinal circuits into functional states after the loss of brain input.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Analysis of Variance; Animals; Biomechanical Phenomena; Brai | 2009 |
Transformation of nonfunctional spinal circuits into functional states after the loss of brain input.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Analysis of Variance; Animals; Biomechanical Phenomena; Brai | 2009 |
Transformation of nonfunctional spinal circuits into functional states after the loss of brain input.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Analysis of Variance; Animals; Biomechanical Phenomena; Brai | 2009 |
Transformation of nonfunctional spinal circuits into functional states after the loss of brain input.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Analysis of Variance; Animals; Biomechanical Phenomena; Brai | 2009 |
Transformation of nonfunctional spinal circuits into functional states after the loss of brain input.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Analysis of Variance; Animals; Biomechanical Phenomena; Brai | 2009 |
Transformation of nonfunctional spinal circuits into functional states after the loss of brain input.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Analysis of Variance; Animals; Biomechanical Phenomena; Brai | 2009 |
Transformation of nonfunctional spinal circuits into functional states after the loss of brain input.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Analysis of Variance; Animals; Biomechanical Phenomena; Brai | 2009 |
Transformation of nonfunctional spinal circuits into functional states after the loss of brain input.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Analysis of Variance; Animals; Biomechanical Phenomena; Brai | 2009 |
Transformation of nonfunctional spinal circuits into functional states after the loss of brain input.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Analysis of Variance; Animals; Biomechanical Phenomena; Brai | 2009 |
Transformation of nonfunctional spinal circuits into functional states after the loss of brain input.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Analysis of Variance; Animals; Biomechanical Phenomena; Brai | 2009 |
Transformation of nonfunctional spinal circuits into functional states after the loss of brain input.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Analysis of Variance; Animals; Biomechanical Phenomena; Brai | 2009 |
Transformation of nonfunctional spinal circuits into functional states after the loss of brain input.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Analysis of Variance; Animals; Biomechanical Phenomena; Brai | 2009 |
Transformation of nonfunctional spinal circuits into functional states after the loss of brain input.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Analysis of Variance; Animals; Biomechanical Phenomena; Brai | 2009 |
Transformation of nonfunctional spinal circuits into functional states after the loss of brain input.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Analysis of Variance; Animals; Biomechanical Phenomena; Brai | 2009 |
Transformation of nonfunctional spinal circuits into functional states after the loss of brain input.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Analysis of Variance; Animals; Biomechanical Phenomena; Brai | 2009 |
Transformation of nonfunctional spinal circuits into functional states after the loss of brain input.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Analysis of Variance; Animals; Biomechanical Phenomena; Brai | 2009 |
Transformation of nonfunctional spinal circuits into functional states after the loss of brain input.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Analysis of Variance; Animals; Biomechanical Phenomena; Brai | 2009 |
Transformation of nonfunctional spinal circuits into functional states after the loss of brain input.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Analysis of Variance; Animals; Biomechanical Phenomena; Brai | 2009 |
Transformation of nonfunctional spinal circuits into functional states after the loss of brain input.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Analysis of Variance; Animals; Biomechanical Phenomena; Brai | 2009 |
Transformation of nonfunctional spinal circuits into functional states after the loss of brain input.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Analysis of Variance; Animals; Biomechanical Phenomena; Brai | 2009 |
Transformation of nonfunctional spinal circuits into functional states after the loss of brain input.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Analysis of Variance; Animals; Biomechanical Phenomena; Brai | 2009 |
Transformation of nonfunctional spinal circuits into functional states after the loss of brain input.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Analysis of Variance; Animals; Biomechanical Phenomena; Brai | 2009 |
Transformation of nonfunctional spinal circuits into functional states after the loss of brain input.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Analysis of Variance; Animals; Biomechanical Phenomena; Brai | 2009 |
Transformation of nonfunctional spinal circuits into functional states after the loss of brain input.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Analysis of Variance; Animals; Biomechanical Phenomena; Brai | 2009 |
5-hydroxytryptamine 2C receptors in the basolateral amygdala are involved in the expression of anxiety after uncontrollable traumatic stress.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Aminopyridines; Amygdala; Analysis of Variance; Animals; Ani | 2010 |
Differential effects of acute and repeated citalopram in mouse models of anxiety and depression.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antidepressive Agents, Second-Generation; Anxiety; | 2010 |
The modified Geller-Seifter test in rats was insensitive to GABAB receptor positive modulation or blockade, or 5-HT1A receptor activation.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Anxiety; Behavior, Animal; Conditioning, Operant; C | 2010 |
Neuronal nitric oxide synthase alteration accounts for the role of 5-HT1A receptor in modulating anxiety-related behaviors.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Animals, Newborn; Anxiety Disorders; CREB-Binding P | 2010 |
Dorsal raphe nucleus regulation of a panic-like defensive behavior evoked by chemical stimulation of the rat dorsal periaqueductal gray matter.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Disease Models, Animal; Escape Reaction; Homocystei | 2010 |
F15599, a preferential post-synaptic 5-HT1A receptor agonist: activity in models of cognition in comparison with reference 5-HT1A receptor agonists.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Aminopyridines; Animals; Cognition; Disease Models, Animal; | 2010 |
The serotonin transporter plays an important role in male sexual behavior: a study in serotonin transporter knockout rats.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Disease Models, Animal; Ejaculation; Humans; Male; | 2011 |
Juvenile stress attenuates the dorsal hippocampal postsynaptic 5-HT1A receptor function in adult rats.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Age Factors; Animals; Disease Models, Animal; Fear; Freezing | 2011 |
8-OH-DPAT prevents morphine-induced apoptosis in rat dorsal raphe nucleus: a possible mechanism for attenuating morphine tolerance.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Analgesics, Opioid; Animals; Apoptosis; Disease Models, Anim | 2010 |
A new female rat animal model for hypoactive sexual desire disorder; behavioral and pharmacological evidence.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Apomorphine; Disease Models, Animal; Dopamine Agoni | 2011 |
Evaluation of the anxiolytic-like effects of clomipramine in two rat strains with different anxiety vulnerability (Wistar and Wistar-Kyoto rats): participation of 5-HT1A receptors.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Anti-Anxiety Agents; Anxiety; Behavior, Animal; Clo | 2011 |
Motor deficits and recovery in rats with unilateral spinal cord hemisection mimic the Brown-Sequard syndrome.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Apomorphine; Brown-Sequard Syndrome; Clonidine; Dis | 2011 |
Sexually dimorphic serotonergic dysfunction in a mouse model of Huntington's disease and depression.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Behavior, Animal; Depression; Disease Models, Anima | 2011 |
Improving voiding efficiency in the diabetic rat by a 5-HT1A serotonin receptor agonist.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Diabetes Mellitus, Experimental; Disease Models, An | 2012 |
Facilitation of hypothermia by quinpirole and 8-OH-DPAT in a rat model of cardiac arrest.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Body Temperature; Cardiopulmonary Resuscitation; Di | 2012 |
Selective siRNA-mediated suppression of 5-HT1A autoreceptors evokes strong anti-depressant-like effects.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Administration, Intranasal; Animals; Antidepressive Agents; | 2012 |
Susceptibility to the long-term anxiogenic effects of an acute stressor is mediated by the activation of the glucocorticoid receptors.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Analysis of Variance; Animals; Anti-Anxiety Agents; Cocaine; | 2011 |
Essential role for orbitofrontal serotonin 1B receptors in obsessive-compulsive disorder-like behavior and serotonin reuptake inhibitor response in mice.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Acoustic Stimulation; Adrenergic beta-Antagonists; Adrenergi | 2011 |
Effects of fenfluramine, 8-OH-DPAT, and tryptophan-enriched diet on the high-ethanol intake by rats bred for susceptibility to stress.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Alcohol Drinking; Animals; Antidepressive Agents, Second-Gen | 2011 |
Behavioral deficits and exaggerated feedback control over raphe-hippocampal serotonin neurotransmission in restrained rats.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Anxiety; Behavior, Animal; Disease Models, Animal; | 2011 |
Serotonergic modulation of receptor occupancy in rats treated with L-DOPA after unilateral 6-OHDA lesioning.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Analysis of Variance; Animals; Antiparkinson Agents; Autorad | 2012 |
Activation of 5-HT7 serotonin receptors reverses metabotropic glutamate receptor-mediated synaptic plasticity in wild-type and Fmr1 knockout mice, a model of Fragile X syndrome.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Disease Models, Animal; Excitatory Postsynaptic Pot | 2012 |
Acute 5-HT₁A autoreceptor knockdown increases antidepressant responses and serotonin release in stressful conditions.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Autoreceptors; Behavior, Animal; Disease Models, An | 2013 |
Serotonin 5-HT(7) receptor blockade reverses behavioral abnormalities in PACAP-deficient mice and receptor activation promotes neurite extension in primary embryonic hippocampal neurons: therapeutic implications for psychiatric disorders.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antipsychotic Agents; Cell Count; Cells, Cultured; | 2012 |
Differential effects of early environmental enrichment on emotionality related behaviours in Huntington's disease transgenic mice.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Anxiety; Behavior, Animal; Depression; Disease Mode | 2013 |
Long-lasting effects of sepsis on circadian rhythms in the mouse.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antigens, Differentiation; Behavior, Animal; CD11b | 2012 |
Quinpirole and 8-OH-DPAT induce compulsive checking behavior in male rats by acting on different functional parts of an OCD neurocircuit.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Behavior, Animal; Brain; Compulsive Behavior; Disea | 2013 |
Serotonergic pharmacotherapy promotes cortical reorganization after spinal cord injury.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Analysis of Variance; Animals; Brain Mapping; Cerebral Corte | 2013 |
Sex- and endocrine-stage-differences in middle-aged rats in an animal model of OCD.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Age Factors; Analysis of Variance; Animals; Disease Models, | 2013 |
Inhibition of tryptophan hydroxylase activity and decreased 5-HT1A receptor binding in a mouse model of Huntington's disease.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Aging; Animals; Binding, Competitive; Blotting, Western; Bra | 2002 |
Influence of postweaning social isolation in the rat on brain development, conditioned behavior, and neurotransmission.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Action Potentials; Adrenergic Agents; Amphetamine; Analysis | 2003 |
Effects of electrical stimulation or lesion in nucleus accumbens on the behaviour of rats in a T-maze after administration of 8-OH-DPAT or vehicle.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Behavior, Animal; Disease Models, Animal; Electric | 2003 |
Evaluation of the ocular hypotensive response of serotonin 5-HT1A and 5-HT2 receptor ligands in conscious ocular hypertensive cynomolgus monkeys.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; CHO Cells; Cricetinae; Disease Models, Animal; Enzy | 2003 |
Behavioral, neurochemical, and electrophysiological characterization of a genetic mouse model of depression.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Adaptation, Psychological; Animals; Antidepressive Agents; A | 2003 |
The dorsal raphe nucleus exerts opposed control on generalized anxiety and panic-related defensive responses in rats.
Topics: 5,7-Dihydroxytryptamine; 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Anxiety; Avoidance Learnin | 2003 |
Early life adversity programs changes in central 5-HT neuronal function in adulthood.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Adrenergic alpha-Agonists; Analysis of Variance; Animals; An | 2003 |
5-HT(1A) receptor subsensitivity in infancy and supersensitivity in adulthood in an animal model of depression.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Aging; Animals; Animals, Newborn; Behavior, Animal; Body Tem | 2003 |
Buspirone raises blood pressure through activation of sympathetic nervous system and by direct activation of alpha1-adrenergic receptors after severe hemorrhage.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Blood Pressure; Buspirone; Disease Models, Animal; | 2004 |
Combined treatment of quetiapine with haloperidol in animal models of antipsychotic effect and extrapyramidal side effects: comparison with risperidone and chlorpromazine.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Administration, Oral; Animals; Antipsychotic Agents; Basal G | 2004 |
Sex differences on spontaneous alternation in prepubertal rats: implications for an animal model of obsessive-compulsive disorder.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Aging; Animals; Behavior, Animal; Disease Models, Animal; Fe | 2004 |
Prepulse inhibition of acoustic startle in spontaneously hypertensive rats.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Acoustic Stimulation; Adrenergic Agents; Amphetamine; Analys | 2004 |
The 5HT1A receptor agonist, 8-OH-DPAT, protects neurons and reduces astroglial reaction after ischemic damage caused by cortical devascularization.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Astrocytes; Brain Ischemia; Cell Death; Cerebral Co | 2004 |
Evidence that the 5-HT1A autoreceptor is an important pharmacological target for the modulation of cocaine behavioral stimulant effects.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Autoreceptors; Behavior, Animal; Brain; Central Ner | 2005 |
8-hydroxy-2-(di-n-propylamino)tetralin reduces striatal glutamate in an animal model of Parkinson's disease.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Aspartic Acid; Corpus Striatum; Denervation; Diseas | 2005 |
A serotonin 5-HT1A receptor agonist prevents behavioral sensitization to L-DOPA in a rodent model of Parkinson's disease.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antiparkinson Agents; Behavior, Animal; Corpus Stri | 2005 |
Compulsive-like behaviour according to the sex and the reproductive stage of female rats.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Analysis of Variance; Animals; Choice Behavior; Compulsive B | 2005 |
Participation of the 5-HT1A receptor in the antidepressant-like effect of estrogens in the forced swimming test.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Analysis of Variance; Animals; Antidepressive Agents; Behavi | 2006 |
Effects of inactivation of serotonergic neurons of the median raphe nucleus on learning and performance of contextual fear conditioning.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Anxiety Disorders; Behavior, Animal; Conditioning, | 2005 |
Individual differences in male rat ejaculatory behaviour: searching for models to study ejaculation disorders.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Analysis of Variance; Animals; Apomorphine; Behavior, Animal | 2005 |
Perospirone, a novel antipsychotic drug, inhibits marble-burying behavior via 5-HT1A receptor in mice: implications for obsessive-compulsive disorder.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antipsychotic Agents; Behavior, Animal; Disease Mod | 2005 |
Influence of the post-ovariectomy time frame on the experimental anxiety and the behavioural actions of some anxiolytic agents.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Analysis of Variance; Animals; Anti-Anxiety Agents; Anxiety; | 2006 |
Suppression of bladder reflex activity in chronic spinal cord injured cats by activation of serotonin 5-HT1A receptors.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Cats; Chronic Disease; Disease Models, Animal; Fema | 2006 |
Hypothermic responses to 8-OH-DPAT in the Ts65Dn mouse model of Down syndrome.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Brain; Disease Models, Animal; Down Syndrome; G Pro | 2006 |
Factors producing a menopausal depressive-like state in mice following ovariectomy.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Affect; Amphetamines; Animals; Depression; Disease Models, A | 2006 |
Contribution of spinal 5-HT1A and 5-HT7 receptors to locomotor-like movement induced by 8-OH-DPAT in spinal cord-transected mice.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Disease Models, Animal; Efferent Pathways; Locomoti | 2006 |
GLC756 decreases TNF-alpha via an alpha2 and beta2 adrenoceptor related mechanism.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Adrenergic alpha-Agonists; Adrenergic beta-2 Receptor Antago | 2006 |
Cellular and behavioral effects of 5-HT1A receptor agonist 8-OH-DPAT in a rat model of levodopa-induced motor complications.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antiparkinson Agents; Behavior, Animal; Benserazide | 2007 |
Acute treatment with the 5-HT(1A) receptor agonist 8-OH-DPAT and chronic environmental enrichment confer neurobehavioral benefit after experimental brain trauma.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Behavior, Animal; Brain Injuries; Cognition; Diseas | 2007 |
Postsynaptic 5-HT1A receptor stimulation increases motor activity in the 6-hydroxydopamine-lesioned rat: implications for treating Parkinson's disease.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Analysis of Variance; Animals; Behavior, Animal; Brain Chemi | 2007 |
Baroreceptor-mediated inhibition of respiration after peripheral and central administration of a 5-HT1A receptor agonist in neonatal piglets.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Animals, Newborn; Blood Pressure; Catheterization; | 2007 |
Role of serotonin 5-HT1A and opioid receptors in the antiallodynic effect of tramadol in the chronic constriction injury model of neuropathic pain in rats.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Analgesics, Opioid; Animals; Chronic Disease; Disease Models | 2007 |
Persistence of eupnea and gasping following blockade of both serotonin type 1 and 2 receptors in the in situ juvenile rat preparation.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Decerebrate State; Disease Models, Animal; Dose-Res | 2007 |
Serotonin-1A receptor responsiveness in stress and following adaptation to stress.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Adaptation, Psychological; Animals; Anxiety; Behavior, Anima | 2007 |
Seizure activity selectively reduces 5-HT1A receptor immunoreactivity in CA1 interneurons in the hippocampus of seizure-prone gerbils.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Analysis of Variance; Animals; Cell Count; Disease Models, A | 2007 |
Impaired serotonergic regulation of heart rate may underlie reduced baroreflex sensitivity in an animal model of depression.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Autonomic Nervous System; Baroreflex; Blood Pressur | 2008 |
Neuroprotective effects of serotonin 5-HT 1A receptor activation against ischemic cell damage in gerbil hippocampus: Involvement of NMDA receptor NR1 subunit and BDNF.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Analysis of Variance; Animals; Brain-Derived Neurotrophic Fa | 2008 |
Increase in the effectiveness of somatodendritic 5-HT-1A receptors in a rat model of tardive dyskinesia.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Corpus Striatum; Disease Models, Animal; Dopamine A | 2007 |
Lasting syndrome of depression produced by reduction in serotonin uptake during postnatal development: evidence from sleep, stress, and behavior.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Analysis of Variance; Animals; Animals, Newborn; Antidepress | 2008 |
Synergistic effects of D1/5 and 5-HT1A/7 receptor agonists on locomotor movement induction in complete spinal cord-transected mice.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Analysis of Variance; Animals; Behavior, Animal; Benzazepine | 2008 |
Evaluation of the antibradykinetic actions of 5-HT1A agonists using the mouse pole test.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antipsychotic Agents; Behavior, Animal; Disease Mod | 2008 |
Effects of serotonin1A agonists on anoxia-induced impairment of protein synthesis in rat brain slices.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Brain; Brain Ischemia; Buspirone; Carbon Isotopes; | 1995 |
Socially defeated male rats display a blunted adrenocortical response to a low dose of 8-OH-DPAT.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Adrenal Cortex; Aggression; Animals; Behavior, Animal; Cardi | 1995 |
Behavioural and pharmacological characterisation of the elevated "zero-maze" as an animal model of anxiety.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Anti-Anxiety Agents; Anxiety; Behavior, Animal; Chl | 1994 |
Ultrasound vocalization is not related to corticosterone response in isolated rat pups.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Animals, Newborn; Anxiety; Buspirone; Corticosteron | 1994 |
Swim test immobility co-segregates with serotonergic but not cholinergic sensitivity in cross-breeds of Flinders Line rats.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Analysis of Variance; Animals; Depressive Disorder; Disease | 1994 |
The hypophagic effect of restraint stress in rats can be mediated by 5-HT2 receptors in the paraventricular nucleus of the hypothalamus.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Amidines; Animals; Anorexia; Anorexia Nervosa; Disease Model | 1993 |
Attenuation of CCK-induced aversion in rats on the elevated x-maze by the selective 5-HT1A receptor antagonists (+) WAY100135 and WAY100635.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Anxiety; Behavior, Animal; Cholecystokinin; Disease | 1995 |
Serotonergic mechanisms involved in the exploratory behaviour of mice in a fully automated two-compartment black and white text box.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Adrenergic beta-Antagonists; Animals; Anti-Anxiety Agents; A | 1995 |
Effect of isolation on behavioural models involving serotonergic 5-HT2 and 5-HT1A receptors.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Behavior, Animal; Disease Models, Animal; Hypotherm | 1995 |
The effect of 5-HT1A receptor ligands in a chronic mild stress model of depression.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Citalopram; Depressive Disorder; Disease Models, An | 1995 |
Augmented responses to 5-HT2-receptor-mediated vasoconstrictions in atherosclerotic rabbit common carotid arteries.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Arteriosclerosis; Carotid Arteries; Disease Models, | 1995 |
Differential responsiveness of inbred strains of rats to antidepressants in the forced swimming test: are Wistar Kyoto rats an animal model of subsensitivity to antidepressants?
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antidepressive Agents; Behavior, Animal; Desipramin | 1996 |
Pre- or postsynaptic activity of 5-HT1A compounds in mice depends on the anxiety paradigm.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Anxiety; Behavior, Animal; Buspirone; Disease Model | 1996 |
Cholinergic/serotonergic interactions in hypothermia: implications for rat models of depression.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Aging; Animals; Body Temperature Regulation; Depressive Diso | 1998 |
Pharmacological features of masculine sexual behavior in an animal model of depression.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Adrenergic alpha-Antagonists; Animals; Animals, Newborn; Clo | 1998 |
Combining pindolol and paroxetine in an animal model of chronic antidepressant action--can early onset of action be detected?
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Adrenergic beta-Antagonists; Animals; Antidepressive Agents; | 1998 |
The 5-HT1A agonist 8-OH-DPAT increases the number of spike-wave discharges in a genetic rat model of absence epilepsy.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Action Potentials; Animals; Disease Models, Animal; Dose-Res | 1998 |
Animal models for studying serotonin (5-HT) receptor subtypes: relationship to 5-HT system pathologies.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Anxiety; Avoidance Learning; Disease Models, Animal | 1998 |
Activity and onset of action of reboxetine and effect of combination with sertraline in an animal model of depression.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Amygdala; Analgesics; Animals; Antidepressive Agents; Body T | 1999 |
A serotonin-1A receptor agonist and an N-methyl-D-aspartate receptor antagonist oppose each others effects in a genetic rat epilepsy model.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Action Potentials; Animals; Brain Chemistry; Disease Models, | 1999 |
Anxiolytic effect of intra-amygdala injection of midazolam and 8-hydroxy-2-(di-n-propylamino)tetralin in the elevated T-maze.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Amygdala; Analysis of Variance; Animals; Anti-Anxiety Agents | 1999 |
Onset of the effects of the 5-HT1A antagonist, WAY-100635, alone, and in combination with paroxetine, on olfactory bulbectomy and 8-OH-DPAT-induced changes in the rat.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antidepressive Agents, Second-Generation; Depressio | 1999 |
Latency to paroxetine-induced anxiolysis in the rat is reduced by co-administration of the 5-HT(1A) receptor antagonist WAY100635.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Anti-Anxiety Agents; Anxiety; Disease Models, Anima | 2000 |
Memory of an operant response and of depressed mood retained in activation states of 5-HT(1A) receptors: evidence from rodent models.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Analysis of Variance; Animals; Behavior, Animal; Conditionin | 2000 |
Repeated treatment with 8-OH-DPAT induces tolerance to its ability to produce the 5-HT1A behavioural syndrome, but not to its ability to attenuate haloperidol-induced catalepsy.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antipsychotic Agents; Basal Ganglia Diseases; Behav | 2000 |
Rapid desensitization of 5-HT(1A) receptors in Fawn-Hooded rats after chronic fluoxetine treatment.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Anxiety Disorders; Body Temperature; Depressive Dis | 2001 |
Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Anti-Anxiety Agents; Anxiety; Behavior, Animal; Bro | 2001 |
Effect of the serotonin agonist 8-OH-DPAT on the sensorimotor system of the rat.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Disease Models, Animal; Male; Obsessive-Compulsive | 2001 |
Investigations on possible serotonergic involvement in effects of OB-200G (polyherbal preparation) on food intake in female mice.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Disease Models, Animal; Energy Intake; Feeding Beha | 2001 |
Adenosine A2A, 5-HT1A and 5-HT7 receptor in neonatally pregnenolone-treated rats.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Adenosine; Aging; Animals; Animals, Newborn; Antihypertensiv | 2001 |
A chronic treatment with fluoxetine decreases 5-HT(1A) receptors labeling in mice selected as a genetic model of helplessness.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Binding, Competitive; Brain; Depression; Disease Mo | 2002 |
5-Hydroxytryptamine1A receptor agonists in animal models of depression and anxiety.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Anxiety; Buspirone; Chromans; Depression; Disease M | 1992 |
Response suppression induced with selective 5-HT agonists can be differentially blocked with LY53857 in an animal model of depression.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Amphetamines; Animals; Behavior, Animal; Depression; Disease | 1992 |
Spontaneous alternation behavior: an animal model for obsessive-compulsive disorder?
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Behavior, Animal; Disease Models, Animal; Fluoxetin | 1991 |
Higher density of serotonin-1A receptors in the hippocampus and cerebral cortex of alcohol-preferring P rats.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Alcoholism; Animals; Cell Membrane; Cerebral Cortex; Disease | 1990 |
5.HT1 receptors in the vertebrate brain. Regional distribution examined by autoradiography.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Aged; Animals; Autoradiography; Brain; Cats; Disease Models, | 1989 |
Antidepressant-like action of 5-HT1A agonists and conventional antidepressants in an animal model of depression.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Anti-Anxiety Agents; Antidepressive Agents; Benzodi | 1987 |
Evaluation of the 5-hydroxytryptamine receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin in different rodent models of epilepsy.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Anticonvulsants; Convulsants; Disease Models, Anima | 1985 |